Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab and immunosuppressive therapy without first-line plasma exchange in immune-mediated TTP
2024-513262-19-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving remission without requiring therapeutic plasma exchange (TPE). Started Jul 2024; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2024-513262-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513262-19-00.